Local ablative therapy of oligoprogressive TKI-treated thyroid cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
http://link.springer.com/content/pdf/10.1007/s40618-019-1001-x.pdf
Reference66 articles.
1. Droz JP, Schlumberger M, Rougier P et al (1990) Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76(5):480–483
2. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98. https://doi.org/10.1056/NEJMoa011954
3. Schmid TA, Gore ME (2016) Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 8(6):348–371. https://doi.org/10.1177/1756287216663979
4. Sapuppo G, Tavarelli M, Russo M et al (2018) Lymph node location is a risk factor for papillary thyroid cancer-related death. J Endocrinol Invest 41(11):1349–1353. https://doi.org/10.1007/s40618-018-0865-5
5. Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features;Journal of Endocrinological Investigation;2023-04-21
2. Follikuläres Schilddrüsenkarzinom;Springer Reference Medizin;2022-11-12
3. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer;Cancer Medicine;2022-10
4. Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study;JMIR Medical Informatics;2022-04-08
5. Therapy of non-iodine uptaking metastasis in thyroid cancer;Nuclear Medicine and Molecular Imaging;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3